Simone Parello

Dr. Simone Parello

Dipartimento di Medicina e Chirurgia Traslazionale, Catholic University of the Sacred Heart, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ENEnrico Celestino Nista
Enrico Celestino Nista
Simone ParelloSimone Parello
Simone Parello
MBMattia Brigida
Mattia Brigida
GAGiulio Amadei
Giulio Amadei
ASAngela Saviano
Angela Saviano
Veronica OjettiVeronica Ojetti
Veronica Ojetti
Acute pancreatitis (AP) is a common and potentially severe gastrointestinal condition characterized by acute inflammation of the pancreas. The pathophysiology of AP is multifactorial and intricate, involving a cascade of events that lead to pancreatic injury and systemic inflammation. The progression of AP is influenced by many factors, including genetic predispositions, environmental triggers, and immune dysregulation. Recent studies showed a critical involvement of the gut microbiota in shaping the immune response and modulating inflammatory processes during AP. This review aims to provide a comprehensive overview of the emerging role of gut microbiota and probiotics in AP. We analyzed the implication of gut microbiota in pathogenesis of AP and the modification during an acute attack. The primary goals of microbiome-based therapies, which include probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and enteral nutrition, are to alter the composition of the gut microbial community and the amount of metabolites derived from the microbiota. By resetting the entire flora or supplementing it with certain beneficial organisms and their byproducts, these therapeutic approaches aim to eradicate harmful microorganisms, reducing inflammation and avoiding bacterial translocation and the potential microbiota-based therapeutic target for AP from nutrition to pre- and probiotic supplementation to fecal transplantation.

17 October 2025 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Open access
PPPierluigi Puca
Pierluigi Puca
GCGaetano Coppola
Gaetano Coppola
Simone ParelloSimone Parello
Simone Parello
ICIvan Capobianco
Ivan Capobianco
SCStefania Colantuono
Stefania Colantuono
APAlfredo Papa
Alfredo Papa
Inflammatory bowel diseases (IBD) are systemic inflammatory conditions increasingly recognized to confer excess risk of atherosclerotic cardiovascular disease (ASCVD), particularly in younger patients and during periods of active disease. We here synthesize evidence across epidemiology, mechanisms, risk stratification, and management at the IBD-ASCVD interface. Across population cohorts and meta-analyses, IBD associates with modest but consistent increases in ischemic heart disease, cerebrovascular events, and peripheral arterial disease, with higher relative risks for mesenteric ischaemia and for premature events; risk escalates with inflammatory burden and flares, while traditional factors alone partially explain the association. Prolonged corticosteroid exposure correlates with adverse vascular outcomes, whereas effective control of intestinal inflammation, particularly with anti-TNF biologics, appears protective; the absolute cardiovascular risk with Janus kinase inhibitors seems largely determined by baseline risk profile and is low in appropriately selected patients. Proposed drivers include dysbiosis and microbially derived metabolites (e.g., trimethylamine-N-oxide, imidazole propionate), intestinal barrier failure with low-grade endotoxemia and Toll-like receptor-4 activation, neutrophil- and platelet-mediated thromboinflammation, and inflammasome pathways that accelerate atherothrombosis. For risk stratification, non-invasive vascular measures (arterial stiffness, carotid intima-media thickness, coronary artery calcium) and general calculators (SCORE2/ASCVD) are informative, though underestimation in younger patients is possible; expert guidance emphasizes mitigation of inflammatory activity, smoking cessation, prudent steroid use, and lipid monitoring with small-molecule therapy. In conclusion, IBD confers clinically relevant ASCVD risk through immune-microbiome-barrier interactions superimposed on traditional factors. Routine cardiovascular assessment, aggressive control of intestinal inflammation, lifestyle optimization, and judicious therapy selection should be embedded in IBD care, while prospective studies refine prediction tools and test targeted preventive strategies across phenotypes and ages.

11 October 2025 in Behavioral Sciences
Verified
Journal Article
Open access
PDF file
Mattia BozzettiMattia Bozzetti
Mattia Bozzetti
IMIlaria Marcomini
Ilaria Marcomini
Alessio Lo CascioAlessio Lo Cascio
Alessio Lo Cascio
MMMaria Rosaria Magurano
Maria Rosaria Magurano
EREleonora Ribaudi
Eleonora Ribaudi
DNDaniele Napolitano
Daniele Napolitano
Inflammatory bowel disease (IBD) affects not only patients but also their informal caregivers. Enhancing caregiver resilience may improve both caregiver well-being and patient outcomes. This study aimed to assess resilience levels in caregivers of individuals with IBD and identify key psychological and contextual predictors, including caregiver contributions to self-care, self-efficacy, and perceived care load. A multicentre cross-sectional study was conducted across nine IBD outpatient clinics in Italy. Caregiver resilience was measured using the Connor–Davidson Resilience Scale (CD-RISC 25). Additional tools included the Caregiver Contribution to Self-Care of Chronic Illness Inventory (CC-SC-CII) and Caregiver Self-Efficacy in Contributing to Patient Self-Care Scale (CSE-CSC). Robust regression models identified predictors of total resilience and its subdomains. Among 275 caregivers (median age 53; 58.2% female) CD-RISC-25 levels were moderately high (median = 74 [IQR = 65–84]), with no significant differences between those caring for patients with Crohn’s disease or ulcerative colitis. SEM analyses showed that self-efficacy significantly predicted contributions to disease monitoring and management, but not maintenance. In turn, the management dimension was significantly associated with higher levels of resilience across four of five domains (trust, control, acceptance of change, and spirituality), while maintenance was uniquely associated with personal competence. Predictors including education and employment status showed no significant direct or indirect effects on CC-SC-CII. In conclusion, caregiver resilience in IBD is positively associated with self-efficacy and active engagement in disease management. Targeted support strategies may strengthen caregiver resources and promote sustainable care.

18 August 2026 in Psychiatric Quarterly
Verified
Journal Article
Open access
PDF file
DNDaniele Napolitano
Daniele Napolitano
Mattia BozzettiMattia Bozzetti
Mattia Bozzetti
Alessio Lo CascioAlessio Lo Cascio
Alessio Lo Cascio
NONicoletta Orgiana
Nicoletta Orgiana
Simone ParelloSimone Parello
Simone Parello
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
Self-care and illness perception are key determinants of adaptation to inflammatory bowel disease (IBD), but their relationship may be heterogeneous and poorly captured by average-level associations. This multicenter cross-sectional study examined whether self-care behaviors were associated with illness perception and explored whether distinct patient profiles could be identified from their combined behavioral and cognitive-emotional patterns. Between April and June 2024, adult patients were recruited consecutively from nine Italian IBD units and completed validated measures of self-care, illness perception, self-care self-efficacy, and psychological distress. Structural equation modeling was used to test the association between self-care domains and illness perception, followed by unsupervised cluster analysis. Among 450 participants with complete data, the structural equation model showed satisfactory fit, but no self-care domain was significantly associated with illness perception. Four clinically interpretable profiles emerged: Engaged Copers, Overwhelmed and Passive, Detached and Vulnerable, and Minimizers with Functional Engagement. The profiles differed markedly in illness perception and self-care behaviours, with large effect sizes, whereas anxiety and self-care self-efficacy showed statistically significant but small between-profile differences. No statistically significant omnibus differences were observed in generational distribution, exercise habits, or disease activity. These findings suggest that self-care and illness perception are not related through a simple linear association. Person-centered profiling may support tailored self-management education and psychological assessment in routine IBD care.

27 June 2026 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
Simone ParelloSimone Parello
Simone Parello
AGAngelo Del Gaudio
Angelo Del Gaudio
MMMarco Murgiano
Marco Murgiano
FCFabio Cascella
Fabio Cascella
PPPierluigi Puca
Pierluigi Puca
DNDaniele Napolitano
Daniele Napolitano
Bowel urgency (BU) is a highly prevalent and distressing symptom in inflammatory bowel disease (IBD), yet its assessment remains inconsistent and insufficiently standardized. Although recent clinical trials and emerging guidelines increasingly recognize its clinical relevance, no standardized, multidimensional instrument specifically designed to assess BU has been established. This narrative review synthesizes current evidence on the prevalence, clinical and psychosocial burden, prognostic role, and measurement of BU. It outlines key priorities for developing a BU-specific patient-reported outcome (PRO). BU is reported by 30–98% of patients and frequently persists despite clinical or endoscopic remission. BU is independently associated with higher risks of hospitalization, corticosteroid use, colectomy, and disease relapse. Reported psychosocial effects included anxiety, avoidance behaviours, reduced physical activity, decreased work productivity, and impaired health-related quality of life. Existing assessment tools do not fully capture the complexity of BU: traditional disease activity indices overlook urgency, numeric rating scales assess severity alone, and behavioral measures focus on secondary coping strategies. Evidence from trials of JAK inhibitors, S1P modulators, and IL-23 inhibitors supports BU as a sensitive and early marker of treatment response. In conclusion, BU is a prevalent, burdensome, and prognostically relevant symptom in IBD. Current assessment instruments are limited and fail to encompass the emotional, behavioral, and functional dimensions of BU. A multidimensional BU-specific PRO is needed to enhance clinical evaluation, support patient-centered care, and refine outcome assessment in therapeutic trials.